Matthew J. Matasar, MD

Dr Graff discusses perceptions of the future for patients treated with bispecific antibodies for non-Hodgkin lymphoma, highlighting key unmet needs and sharing clinical pearls for community oncologists.

Panelists discuss their perceptions of the future for patients treated with bispecific antibodies for non-Hodgkin lymphoma, highlighting key unmet needs and sharing clinical pearls for community oncologists.

Panelists discuss how they collaborate with community oncology centers when receiving patient referrals for initial or step-up dosing, returning patients to community practices for maintenance dosing, and managing grade 3/4 adverse events related to cytokine release syndrome or neurotoxicity.

Dr Graff discusses her standard approach when initiating bispecific antibody treatment for patients, including whether to refer to an academic center or provide treatment in the community setting and how to manage hospitalization if required.

Dr Graff discusses the differences and similarities in managing adverse events associated with bispecific antibodies in non-Hodgkin lymphoma compared to other therapeutic indications, such as multiple myeloma and non–small cell lung cancer.

Dr Graff discusses the recommendations for identifying, evaluating, and managing neurological toxicities, including workup and evaluation, grading of toxicity, and overall management, also addressing other important toxicities.

Panelists discuss the recommendations for identifying, evaluating, and managing neurological toxicities, including workup and evaluation, grading of toxicity, and overall management. They also address other important toxicities.

Dr Graff discusses the recommendations for evaluating, identifying, and managing cytokine release syndrome (CRS), covering the pretreatment phase, patient education, treatment location, premedications, CRS management, dose modifications, and the community oncology perspective.

Panelists discuss the recommendations for evaluating, identifying, and managing cytokine release syndrome (CRS), covering the pretreatment phase, patient education, treatment location, premedications, CRS management, dose modifications, and the community oncology perspective.

Panelists discuss how they manage cytokine release syndrome and the necessary pretreatment testing to ensure patient safety and effective therapy.

Dr Graff discusses how they developed protocols for administering bispecific antibodies and monitoring and managing associated adverse events.

Panelists discuss how they developed their protocols for administering bispecific antibodies and monitoring and managing associated adverse events.

Dr Graff discusses how to operationalize bispecific antibody (BsAb) therapy in community practices by summarizing the toxicities associated with CD3×CD20 BsAbs and presenting consensus recommendations for their management.

Panelists discuss how to operationalize bispecific antibody (BsAb) therapy in community practices, summarizing the toxicities associated with CD3×CD20 BsAbs and presenting consensus recommendations for their management.

Panelists discuss how bispecific antibodies are transforming the treatment landscape for non-Hodgkin lymphoma by enhancing T cell engagement and targeting malignant B cells effectively.

Matthew Matasar, MD, discusses the next steps for the development of ibrutinib given in combination with venetoclax for patients with mantle cell lymphoma, and potential challenges with using the combination.

Matthew Matasar, MD, discusses how ibrutinib given in combination with venetoclax compares with ibrutinib and placebo for the treatment of patients with relapsed/refractory mantle cell lymphoma.

Matthew Matasar, MD, highlights the use of mosunetuzumab-axgb for the treatment of patients with follicular lymphoma.

Matthew Matasar, MD, discusses the phase 3 SYMPATICO study of ibrutinib given in combination with venetoclax vs ibrutinib and placebo for the treatment of patients with relapsed/refractory mantle cell lymphoma.

Matthew Matasar, MD, discusses the development of mosunetuzumab and how it is a positive step forward in the field of follicular lymphoma treatment.

Closing out their discussion on bispecific antibody therapies, Matthew Matasar, MD and Laurie Sehn, MD, consider ongoing clinical trials and real-world use of these novel agents.

Experts Matthew Matasar, MD and Laurie Sehn, MD, nuance the adverse event profiles of bispecific antibody therapies and consider how these will help inform treatment decisionmaking.

Expert perspectives on the advent of bispecific antibody therapy in relapsed/refractory follicular lymphoma, centered on data and experience with several novel agents.

Shared insight on the development and use of CAR T-cell therapy in patients with multiply relapsed follicular lymphoma.

Switching to the paradigm of multiply relapsed follicular lymphoma, expert participants discuss the rationale behind and use of PI3k- and EZH2- targeted therapies.

Matthew Matasar, MD and Laurie Sehn, MD, share insight on available therapies for relapsed or refractory follicular lymphoma and reflect on factors that help in treatment selection.

Centering discussion on both symptomatic and asymptomatic disease, expert participants highlight cornerstone frontline therapies in follicular lymphoma.

A brief review of the role that PET imaging plays in staging follicular lymphoma and how it may inform treatment decisions.

Key opinion leaders in the management of follicular lymphoma share their perspective on risk stratification and staging strategies to inform treatment decisionmaking.

Opening their discussion on follicular lymphoma, experts Matthew Matasar, MD and Laurie Sehn, MD, reflect on its indolent nature as a subset of non-Hodgkin lymphoma.